Vivodyne provides a preclinical platform that utilizes lab-grown human organ tissue models for drug discovery and development. This platform enables high-throughput testing on thousands of human tissues to generate predictive human data before clinical trials. The resulting multimodal datasets power advanced AI models to refine new therapeutic targets and optimize drug candidates.
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug testing methods rely heavily on animal models, which often fail to accurately predict human responses, leading to inefficiencies and ethical concerns in drug discovery and development. These models can be costly, time-consuming, and may not fully represent the complexities of human biology across various organ systems.
Solution
Vivodyne offers an automated, robotic platform that uses lab-grown human organs to conduct large-scale drug testing, generating clinically predictive data. The platform enables testing on thousands of independent human tissues simultaneously, providing vivarium-scale output within a compact footprint. By integrating advanced multimodal AI, Vivodyne designs and deploys experiments to refine new targets and therapies, leveraging human data to accelerate the pace of discovery. The platform supports various drug modalities, combination therapies, and multiphase regimens, offering a human-relevant alternative to traditional animal testing.
Target Audience
Vivodyne's primary customers are biopharmaceutical companies seeking to improve the efficiency and accuracy of their drug discovery and development process by utilizing human-relevant data.
Features
- Portfolio of over 20 lab-grown human organ models spanning major organ systems, mimicking native human functions and phenotypes
- Robotic Data Engine platforms capable of testing on 10,000+ independent human tissues simultaneously with millisecond precision
- Multimodal AI platform integrating 3D phenomics, single-cell sequencing, and proteomics data
- Active learning system that identifies and produces the most useful human training data on-demand to refine AI accuracy
- Ability to test different drug modalities, combination therapies, and multiphase regimens
- Data-driven insights to refine new targets and therapies